ReShape Historical Income Statement

RSLS Stock

USD 5.56 0.19 3.30%

Historical analysis of ReShape Lifesciences income statement accounts such as Depreciation And Amortization of 146.3 K, Selling General Administrative of 14.4 M, Research Development of 2.2 M or Total Other Income Expense Net of 3.5 M can show how well ReShape Lifesciences performed in making a profits. Evaluating ReShape Lifesciences income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ReShape Lifesciences's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ReShape Lifesciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ReShape Lifesciences is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

About ReShape Income Statement Analysis

ReShape Lifesciences Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ReShape Lifesciences shareholders. The income statement also shows ReShape investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ReShape Lifesciences Income Statement Chart

At this time, ReShape Lifesciences' Other Operating Expenses is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 24.6 M in 2024, whereas Operating Income is likely to drop (15.4 M) in 2024.

Other Operating Expenses Selling General Administrative Research Development Selling And Marketing Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ReShape Lifesciences. It is also known as ReShape Lifesciences overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from ReShape Lifesciences' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Other Operating Expenses is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 24.6 M in 2024, whereas Operating Income is likely to drop (15.4 M) in 2024.

ReShape Lifesciences income statement Correlations

	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Selling General Administrative	Research Development	Income Before Tax	Total Other Income Expense Net	Total Revenue	Gross Profit	Net Income From Continuing Ops	Cost Of Revenue	Non Operating Income Net Other	Discontinued Operations	Net Interest Income	Interest Income	Tax Provision	Reconciled Depreciation	Selling And Marketing Expenses	Non Recurring
Interest Expense		-0.03	0.03	-0.06	-0.05	0.0	0.14	0.59	0.03	-0.02	0.01	0.1	0.11	-0.07	-0.1	0.24	-0.04	0.31	0.23	-0.34	0.35	-0.08	0.09	-0.27	0.15
Other Operating Expenses	-0.03		-0.63	-0.74	-0.71	0.97	-0.59	-0.38	0.42	0.61	-0.36	-0.67	-0.4	0.52	0.51	-0.57	0.52	-0.36	-0.42	0.39	-0.5	0.37	0.54	0.51	-0.42
Operating Income	0.03	-0.63		0.91	0.9	-0.77	0.59	0.53	-0.25	-0.6	-0.13	0.36	0.03	0.22	0.22	0.12	0.22	-0.23	-0.03	0.0	0.07	0.42	0.07	-0.1	-0.32
Ebit	-0.06	-0.74	0.91		0.99	-0.86	0.39	0.4	-0.28	-0.63	-0.17	0.35	-0.03	0.17	0.17	0.12	0.17	-0.23	-0.2	0.18	-0.04	0.28	-0.08	-0.16	-0.28
Ebitda	-0.05	-0.71	0.9	0.99		-0.85	0.4	0.4	-0.18	-0.61	-0.2	0.35	-0.01	0.21	0.21	0.12	0.21	-0.3	-0.24	0.2	-0.08	0.32	-0.02	-0.1	-0.32
Total Operating Expenses	0.0	0.97	-0.77	-0.86	-0.85		-0.53	-0.4	0.36	0.61	-0.2	-0.56	-0.25	0.29	0.29	-0.41	0.29	-0.19	-0.24	0.24	-0.35	0.18	0.35	0.42	-0.21
Net Income	0.14	-0.59	0.59	0.39	0.4	-0.53		0.52	-0.05	-0.55	0.27	0.87	0.77	-0.41	-0.42	0.77	-0.39	0.05	0.52	-0.49	0.46	0.07	-0.36	-0.13	0.18
Income Tax Expense	0.59	-0.38	0.53	0.4	0.4	-0.4	0.52		-0.09	-0.43	0.15	0.33	0.25	-0.09	-0.09	0.25	-0.09	0.08	0.31	-0.31	0.46	0.11	0.05	-0.01	0.05
Depreciation And Amortization	0.03	0.42	-0.25	-0.28	-0.18	0.36	-0.05	-0.09		0.25	-0.26	-0.06	0.16	0.27	0.25	0.02	0.31	-0.57	-0.29	0.17	-0.33	0.34	0.52	0.6	-0.28
Selling General Administrative	-0.02	0.61	-0.6	-0.63	-0.61	0.61	-0.55	-0.43	0.25		-0.39	-0.57	-0.35	0.14	0.13	-0.48	0.14	0.1	-0.1	0.08	-0.34	-0.09	0.22	0.17	0.03
Research Development	0.01	-0.36	-0.13	-0.17	-0.2	-0.2	0.27	0.15	-0.26	-0.39		0.3	0.36	-0.72	-0.72	0.44	-0.73	0.61	0.77	-0.75	0.81	-0.68	-0.37	-0.48	0.76
Income Before Tax	0.1	-0.67	0.36	0.35	0.35	-0.56	0.87	0.33	-0.06	-0.57	0.3		0.9	-0.61	-0.61	0.94	-0.59	0.13	0.44	-0.37	0.41	-0.15	-0.66	-0.22	0.33
Total Other Income Expense Net	0.11	-0.4	0.03	-0.03	-0.01	-0.25	0.77	0.25	0.16	-0.35	0.36	0.9		-0.69	-0.7	0.92	-0.67	0.19	0.53	-0.44	0.45	-0.26	-0.56	0.01	0.44
Total Revenue	-0.07	0.52	0.22	0.17	0.21	0.29	-0.41	-0.09	0.27	0.14	-0.72	-0.61	-0.69		1.0	-0.72	1.0	-0.75	-0.83	0.73	-0.73	0.84	0.77	0.49	-0.93
Gross Profit	-0.1	0.51	0.22	0.17	0.21	0.29	-0.42	-0.09	0.25	0.13	-0.72	-0.61	-0.7	1.0		-0.74	0.99	-0.75	-0.84	0.75	-0.73	0.84	0.75	0.5	-0.94
Net Income From Continuing Ops	0.24	-0.57	0.12	0.12	0.12	-0.41	0.77	0.25	0.02	-0.48	0.44	0.94	0.92	-0.72	-0.74		-0.69	0.28	0.55	-0.53	0.52	-0.35	-0.64	-0.33	0.51
Cost Of Revenue	-0.04	0.52	0.22	0.17	0.21	0.29	-0.39	-0.09	0.31	0.14	-0.73	-0.59	-0.67	1.0	0.99	-0.69		-0.76	-0.82	0.7	-0.74	0.84	0.78	0.47	-0.93
Non Operating Income Net Other	0.31	-0.36	-0.23	-0.23	-0.3	-0.19	0.05	0.08	-0.57	0.1	0.61	0.13	0.19	-0.75	-0.75	0.28	-0.76		0.78	-0.72	0.74	-0.88	-0.5	-0.65	0.87
Discontinued Operations	0.23	-0.42	-0.03	-0.2	-0.24	-0.24	0.52	0.31	-0.29	-0.1	0.77	0.44	0.53	-0.83	-0.84	0.55	-0.82	0.78		-0.96	0.87	-0.69	-0.45	-0.5	0.86
Net Interest Income	-0.34	0.39	0.0	0.18	0.2	0.24	-0.49	-0.31	0.17	0.08	-0.75	-0.37	-0.44	0.73	0.75	-0.53	0.7	-0.72	-0.96		-0.83	0.63	0.29	0.57	-0.8
Interest Income	0.35	-0.5	0.07	-0.04	-0.08	-0.35	0.46	0.46	-0.33	-0.34	0.81	0.41	0.45	-0.73	-0.73	0.52	-0.74	0.74	0.87	-0.83		-0.63	-0.34	-0.44	0.76
Tax Provision	-0.08	0.37	0.42	0.28	0.32	0.18	0.07	0.11	0.34	-0.09	-0.68	-0.15	-0.26	0.84	0.84	-0.35	0.84	-0.88	-0.69	0.63	-0.63		0.56	0.58	-0.95
Reconciled Depreciation	0.09	0.54	0.07	-0.08	-0.02	0.35	-0.36	0.05	0.52	0.22	-0.37	-0.66	-0.56	0.77	0.75	-0.64	0.78	-0.5	-0.45	0.29	-0.34	0.56		0.53	-0.59
Selling And Marketing Expenses	-0.27	0.51	-0.1	-0.16	-0.1	0.42	-0.13	-0.01	0.6	0.17	-0.48	-0.22	0.01	0.49	0.5	-0.33	0.47	-0.65	-0.5	0.57	-0.44	0.58	0.53		-0.57
Non Recurring	0.15	-0.42	-0.32	-0.28	-0.32	-0.21	0.18	0.05	-0.28	0.03	0.76	0.33	0.44	-0.93	-0.94	0.51	-0.93	0.87	0.86	-0.8	0.76	-0.95	-0.59	-0.57

Click cells to compare fundamentals

ReShape Lifesciences Account Relationship Matchups

ReShape Lifesciences income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	451K	2.0M	832K	113K	26K	24.7K
Other Operating Expenses	31.0M	23.8M	41.3M	38.3M	23.3M	26.5M
Operating Income	(15.9M)	(12.5M)	(27.7M)	(27.1M)	(14.6M)	(15.4M)
Ebit	(15.9M)	(12.5M)	(27.7M)	(27.1M)	(14.6M)	(15.4M)
Ebitda	(17.2M)	(10.8M)	(25.8M)	(24.9M)	(14.5M)	(15.2M)
Total Operating Expenses	25.2M	18.7M	36.1M	33.9M	20.2M	24.6M
Net Income	(74.2M)	(21.6M)	(61.9M)	(46.2M)	(11.4M)	(12.0M)
Income Tax Expense	(893K)	(181K)	(106K)	(380K)	52K	49.4K
Depreciation And Amortization	(1.3M)	1.7M	2.0M	2.2M	154K	146.3K
Selling General Administrative	17.2M	10.5M	24.4M	17.3M	10.3M	14.4M
Research Development	3.1M	3.5M	2.5M	2.5M	2.3M	2.2M
Income Before Tax	(75.1M)	(21.8M)	(62.0M)	(46.6M)	(11.3M)	(11.9M)
Total Other Income Expense Net	(59.2M)	(9.4M)	(34.3M)	(4.7M)	3.3M	3.5M
Total Revenue	15.1M	11.3M	13.6M	11.2M	8.7M	5.4M
Gross Profit	9.3M	6.3M	8.3M	6.8M	5.5M	3.2M
Net Income From Continuing Ops	(74.2M)	(21.6M)	(61.9M)	(46.2M)	(26.2M)	(27.5M)
Cost Of Revenue	5.8M	5.0M	5.3M	4.4M	3.1M	2.2M
Non Operating Income Net Other	(282.7K)	(155.4K)	(1.2M)	(7.3M)	(6.6M)	(6.2M)
Net Income Applicable To Common Shares	(74.2M)	(21.6M)	(61.9M)	(46.2M)	(41.6M)	(43.7M)
Net Interest Income	(451K)	(2.0M)	(832K)	(113K)	(151K)	(158.6K)
Tax Provision	(893K)	(181K)	(106K)	(380K)	(35K)	(36.8K)
Reconciled Depreciation	1.7M	1.7M	2.0M	2.2M	662K	628.9K
Selling And Marketing Expenses	4.8M	4.7M	9.2M	14.1M	7.5M	8.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ReShape Historical Income Statement

About ReShape Income Statement Analysis

ReShape Lifesciences Income Statement Chart

Other Operating Expenses

ReShape Lifesciences income statement Correlations

ReShape Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ReShape Lifesciences income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for ReShape Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Ebitda	+ 0.99	Ebit
Cost Of Revenue	+ 0.99	Gross Profit
Total Operating Expenses	+ 0.97	Other Operating Expenses
Net Income From Continuing Ops	+ 0.94	Income Before Tax

Net Interest Income	- 0.96	Discontinued Operations
Non Recurring	- 0.95	Tax Provision
Non Recurring	- 0.94	Gross Profit
Non Recurring	- 0.93	Cost Of Revenue
Non Recurring	- 0.93	Total Revenue
Tax Provision	- 0.88	Non Operating Income Net Other